A phase 3 clinical trial of a promising coronavirus vaccine candidate, developed by the University of Oxford and biopharmaceutical giant AstraZeneca, has been put on hold due to a “suspected serious adverse reaction” in one of the study’s participants, according to a report by STAT news.
The COVID-19 vaccine, known as AZD1222, is considered one of a handful ofand had recently begun clinical testing in the US and the UK. A spokesperson told STAT the hold is “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials.” A review process triggered the pause, according to the spokesperson.
Clinical trials are often placed on pause to investigate the nature of any adverse events. This is exactly how they are supposed to work and why researchers perform stringent phase 3 trials in the first place. They are designed to ensure the highest level of safety before a vaccine is rolled out to the public.
“This, while disappointing, should reassure us that the proper processes and safety precautions being followed, despite the urgency of this pandemic,” said Hassan Vally, an infectious diseases epidemiologist at La Trobe University. “The reality is that these reactions do occur and they need to be examined closely.”
The nature of the adverse reaction is currently unclear, but it is now being investigated and believed to have been in a participant from the UK. They are expected to recover. It is also unclear if the adverse reaction is linked to the vaccine. Vally suggests more information on the event is required. Other researchers suggest it may not be minor side effects.
“Would be good to know what the problem was,” said Katherine Seley-Radtke, a medicinal chemist studying antivirals at the University of Maryland, “but the fact it has put a hold on things sort of speaks for itself.”
STAT reports the event is “having an impact” on other vaccine trials conducted by AstraZeneca and researchers in other trials are reviewing data looking for similar adverse reactions.
AstraZeneca did not immediately respond to a request for comment.
On Aug. 31, the US National Institutes of Health announced approximately 30,000 adult volunteers across the US would be enrolled in the phase 3 trial, which is designed to evaluate the vaccine in a diverse population and monitor for adverse events. The trial is part of Operation Warp Speed, a collaborative effort aimed at accelerating the development of COVID-19 treatments in the US.
Last week, the Australian government announced it would be ordering 33.8 million doses of the vaccine.
This story is developing.
- Pandemic thriller Utopia on Amazon might be the perfect viewing
- 2021 Jaguar F-Pace refreshed with new styling, luxury and tech
- 2020 Halloween full moon: This year’s spooky spectacle brings a rare twist
- The best minimalist wallet for 2020
- NASA chief calls for prioritizing Venus after surprise find hints at alien life
- YouTube is adding a new Shorts feature to rival TikTok and Instagram Reels
- Paul Rudd, world’s youngest 51-year-old, tells fellow kids to mask up
- Jonathan Majors to join MCU as villain Kang the Conquerer, report says
- TikTok ban won’t prevent employees from being paid, US says in filing